@bikechain @ChrisSDTwits @Richard2019 @BioBoom
It's Portuguese, not Spanish. He's stating that because of the lower concentration, higher potency of the antibody against the virus, the cost of producing this antibody is much lower than the cancer drugs they were developing via similar process. So they'll be able to ramp up production and bring it to market efficiently and affordably.
SRNE is kind of genius having these partnerships and subsidiaries, including this Ark Animal Health subsidiary, giving them an additional market for their product and makes testing/development of drugs easier/faster.